Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European journal of medicinal chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2015.11.012PMID 26599532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.

  2015cited by this paper
• Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors.

  2015cited by this paper
• Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.

  2014cited by this paper
• New frontiers in kinases: second generation inhibitors.

  2014cited by this paper
• Improved and Scalable Preparation of 6-Bromo-4-Chlorothieno[2,3-d]Pyrimidine

  2014cited by this paper
• Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.

  2014cited by this paper
• ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.

  2014cited by this paper
• Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.

  2014cited by this paper
• Solvent selection in synthesis of 4-(1-arylfluoroethoxy)quinazolines and thienopyrimidines

  2013cited by this paper
• Metabolism-guided drug design

  2013cited by this paper
• Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

  2013cited by this paper
• Kinase drug discovery--what's next in the field?

  2013cited by this paper
• Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.

  2013cited by this paper
• Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases

  2012cited by this paper
• Copper-catalyzed oxidative amidation of aldehydes with amine salts: synthesis of primary, secondary, and tertiary amides.

  2012cited by this paper
• Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.

  2012cited by this paper
• Isolation, synthesis, and biological activity of biphenyl and m-terphenyl-type compounds from Dictyostelium cellular slime molds

  2012cited by this paper
• Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

  2012cited by this paper
• Route selection in the synthesis of C-4 and C-6 substituted thienopyrimidines

  2012cited by this paper
• Design , Synthesis , and Structure − Activity Relationships of Novel Pyrazolo [ 5 , 1 ‐ b ] thiazole Derivatives as Potent and Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists

  2012cited by this paper
• Bridging solubility between drug discovery and development.

  2012cited by this paper
• Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.

  2012cited by this paper
• Rational Drug Design of Kinase Inhibitors for Signal Transduction Therapy

  2011cited by this paper
• Follow-on drugs: how far should chemists look?

  2011cited by this paper
• Synopsis of some recent tactical application of bioisosteres in drug design.

  2011cited by this paper
• Chapter 3:The Learning and Evolution of Medicinal Chemistry against Kinase Targets

  2011cited by this paper
• How many "me-too" drugs is too many?

  2011cited by this paper
• Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.

  2011cited by this paper
• Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.

  2010cited by this paper
• Lipophilicity in drug discovery

  2010cited by this paper
• Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization

  2010cited by this paper
• Activity landscape representations for structure-activity relationship analysis.

  2010cited by this paper
• A Medicinal Chemist’s Guide to Molecular Interactions

  2010cited by this paper
• Palladium-Catalyzed One-Pot Conversion of Aldehydes to Amides

  2010cited by this paper
• Chapter 2:ADMET for the Medicinal Chemist

  2010cited by this paper
• Effect of fused benzene ring on rotational barriers of 2,2'-bifuran, 2-phenylfuran, biphenyl, and their benzo analogues

  2009cited by this paper
• Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

  2009cited by this paper
• The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists.

  2009cited by this paper
• 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

  2008cited by this paper
• Molecular docking/dynamics studies of Aurora A kinase inhibitors.

  2008cited by this paper
• ADME Properties of Drugs

  2008cited by this paper
• Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

  2008cited by this paper
• Post-synthetic modification of tagged metal-organic frameworks.

  2008cited by this paper
• Twist angles and torsional potentials of 2,2'-bibenzothiophene, 2,2'-biindole, and 2,2'-bibenzofuran

  2007cited by this paper
• A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development.

  2007cited by this paper
• Novel procedure for modeling ligand/receptor induced fit effects.

  2006cited by this paper
• Use of an Induced Fit Receptor Structure in Virtual Screening

  2006cited by this paper
• Direct conversion of aldehydes to amides, tetrazoles, and triazines in aqueous media by one-pot tandem reactions.

  2003cited by this paper
• Screening for human ADME/Tox drug properties in drug discovery.

  2001cited by this paper
• A New Bromination Method for Phenols and Anisoles: NBS/HBF(4).Et(2)O in CH(3)CN.

  1997cited by this paper
• A New Bromination Method for Phenols and Anisoles: NBS/HBF4·Et2O in CH3CN

  1997cited by this paper
• Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

  1995cited by this paper
• A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

  1995cited by this paper

• Pyridothienopyrimidine Derivatives in Antimicrobial Research: A Review Article on Synthetic Strategies and Therapeutic Potential Against Drug‐Resistant Pathogens

  2026cites this paper
• Design, Synthesis, and Evaluation of β‑Lactamase Inhibitors as Potential Therapeutics for Antimicrobial Resistance

  2025cites this paper
• Design and Synthesis of New Tetrahydrobenzo [4,5]thieno[2,3-d]pyrimidine derivatives as VEGFR2 inhibitors affecting the Bax/Bcl-2 in the HepG2 cancer cells

  2025cites this paper
• Thiourea compounds as multifaceted bioactive agents in medicinal chemistry.

  2025cites this paper
• Designing Potent Anti-Cancer Agents: Synthesis and Molecular Docking Studies of Thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine Derivatives

  2024cites this paper
• Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

  2024cites this paper
• Theoretical study of the antioxidant mechanism and structure-activity relationships of 1,3,4-oxadiazol-2-ylthieno[2,3-d]pyrimidin-4-amine derivatives: a computational approach

  2024cites this paper
• Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells

  2024cites this paper
• Synthesis of a novel fused thieno‐pyrimidine with tetrazole analogs

  2024cites this paper
• Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma.

  2023cites this paper
• Design, Synthesis of Dioxopiperidinamide Derivatives by Amide Coupling Reaction and Study of Their Biological Activity

  2023cites this paper
• Design, Synthesis, and Molecular Docking Studies of Integrated Benzylidenethiazolidine‐2,4‐Dione and Thieno[2,3‐d]pyrimidine‐6‐Carboxylate Derivatives as Potent Antidiabetic agents

  2023cites this paper
• Activation of multiple stress responses in Staphylococcus aureus substantially lowers the minimal inhibitory concentration when combining two novel antibiotic drug candidates

  2023cites this paper
• Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form

  2023cites this paper
• Recent updates on thienopyrimidine derivatives as anticancer agents

  2023cites this paper
• Halogenated Pyrrolopyrimidines with Low MIC on Staphylococcus aureus and Synergistic Effects with an Antimicrobial Peptide

  2022cites this paper
• 1 Design , Synthesis and Biological Evaluation of 6-Substituted Thieno [ 3 , 2-d ] pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

  2022cites this paper
• A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship

  2022cites this paper
• Synthetic Strategies towards Imidazopyridinones and 7‐Azaoxindoles and their Evaluation as Antibacterial Agents

  2021cites this paper
• Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.

  2021cites this paper
• Rapid Access to Kinase Inhibitor Pharmacophores by Regioselective C-H Arylation of Thieno[2,3-d]pyrimidine.

  2020cites this paper
• Synthesis and Anticancer Activity of Functionalized Thieno[2,3-d]pyrimidine Compounds and Their Triazinyl and Tetrazinyl Derivatives

  2020cites this paper
• Design and Rapid Microwave Irradiated One-Pot Synthesis of Tetrahydropyrimidine Derivatives and Their Screening In Vitro Antidiabetic Activity

  2020cites this paper
• Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.

  2019cites this paper
• Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors.

  2019cites this paper
• Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.

  2019cites this paper
• Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy

  2019cites this paper
• Synthesis and characterization of novel 1,6-dihydropyrimidine derivatives for their pharmacological properties

  2019cites this paper
• Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.

  2019cites this paper
• Anticancer Properties of Halogenated Pyrrolo[3,2‐d]pyrimidines with Decreased Toxicity via N5 Substitution

  2018cites this paper
• Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress

  2018cites this paper
• Iridium-catalyzed oxidative Ar–H/Ar–H cross-coupling of primary benzamides with thiophenes

  2018cites this paper
• HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.

  2018cites this paper
• Identification of fused pyrimidines as interleukin 17 secretion inhibitors.

  2018cites this paper
• Synthesis, cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain at C2 position.

  2018cites this paper
• PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.

  2018cites this paper
• Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.

  2017cites this paper
• On-column trypsinization allows for re-use of matrix in modified multiplexed inhibitor beads assay.

  2017cites this paper
• Investigation of Heck coupling on 6-bromo[2,3-d]thienopyrimidines for construction of new EGFR inhibitor lead structures

  2017cites this paper
• Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe.

  2017cites this paper
• Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents.

  2017cites this paper
• Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold

  2017cites this paper
• Newest Developments in the Preparation of Thieno[2,3-d]pyrimidines

  2017cites this paper
• Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors.

  2016cites this paper
• Aryloxymethyltrifluoroborates for Rhodium-Catalyzed Asymmetric Conjugate Arylation. o-Methoxyarylation through 1,4-Rhodium Shift.

  2016cites this paper